Starting Ocrevus Zunovo earlier versus later in relapsing multiple sclerosis
Compares early and later Ocrevus Zunovo treatment in adults with relapsing multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Early Versus Delayed Start of Ocrevus Zunovo for Relapsing Multiple Sclerosis
Key facts
- Where
- Oklahoma City, United StatesSee the site
Where in United States
- Oklahoma Medical Research FoundationOklahoma City, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Oklahoma Medical Research Foundation
- Trial code
- NCT07878923
- Record updated
- 16 October 2026
- Original description
This study will compare starting Ocrevus Zunovo soon after an active episode of relapsing multiple sclerosis (MS) with starting it later. Researchers want to learn whether starting treatment sooner reduces the number of MS relapses over 18 months. They will also study changes in immune cells, blood markers, disability, and MRI scans.Read full original descriptionShow less
Starting Treatment at Time Zero With Ocrevus Zunovo (STAT Ocrevus Zunovo)
This study will compare starting Ocrevus Zunovo soon after an active episode of relapsing multiple sclerosis (MS) with starting it later. Researchers want to learn whether starting treatment sooner reduces the number of MS relapses over 18 months. They will also study changes in immune cells, blood markers, disability, and MRI scans.
About 35 adults with relapsing MS will take part at Oklahoma Medical Research Foundation or Corewell Health West. One group will start Ocrevus Zunovo before leaving the clinic or hospital. The other group will start treatment later. Ocrevus Zunovo is given as an injection under the skin. Participants will have blood draws and follow-up visits for up to 18 months. Researchers will also review their medical records for relapses, steroid treatments, emergency department visits, and hospital stays.
About 10 adults without MS will provide blood samples to help researchers compare immune cell measurements.
Inclusion: Age 18 years or older; Diagnosis of relapsing-remitting multiple sclerosis according to the 2017 McDonald criteria; At least one gadolinium-enhancing lesion on an MRI of the brain, cervical spine, or thoracic spine within 4 weeks of relapse or hospitalization; Age 18 years or older; Able and willing to provide written informed consent and undergo study blood draws; No diagnosis or history of multiple sclerosis, clinically isolated syndrome, or another inflammatory or demyelinating disorder of the central nervous system; In generally good health, as determined by medical history and investigator review.
Exclusion: Contraindication to or intolerance of oral or intravenous corticosteroids; Treatment with an anti-CD20 or other B-cell-depleting therapy within 6 months before enrollment; Active hepatitis B; Allergy to gadolinium contrast or known allergy to ocrelizumab; Another known neurological disorder, including a history of progressive multifocal leukoencephalopathy; Active bacterial, viral, fungal, or mycobacterial infection, or a history of recurrent aspiration pneumonia requiring antibiotic treatment; A condition that may require chronic systemic corticosteroids or immunosuppressants during the study; Active cancer or malignancy; Multiple sclerosis, clinically isolated syndrome, myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), or another neurological disorder that may affect study results; An autoimmune, inflammatory, hematologic, or immunodeficiency disorder that may affect B- or T-cell measurements; Active bacterial, viral, fungal, or mycobacterial infection at enrollment or blood collection; Current use of a disease-modifying therapy, B-cell-depleting therapy, systemic immunosuppressant, immunomodulatory therapy, or chronic systemic corticosteroids; Active cancer or malignancy, except adequately treated localized skin cancer if permitted by the investigator; A medical condition that, in the investigator's judgment, could increase risk, interfere with participation, or affect interpretation of immune cell or biomarker results; Diagnosis of primary progressive multiple sclerosis; Current pregnancy; Unable to complete an MRI; Prisoner status; Limited English-speaking capacity; Unable to provide informed consent; Healthy Control Participants; Current pregnancy; Unable or unwilling to undergo blood collection; Prisoner status; Limited English-speaking capacity; Unable to provide informed consent.
Participants With Relapsing Multiple Sclerosis (Rapid-Start and Delayed-Start Cohorts).